Final 5‐year results of Z‐FAST trial

A. Brufsky,W. G. Harker,J. Beck,L. Bosserman,C. Vogel,C. Seidler,Lixian Jin,G. Warsi,E. Argonza-Aviles,J. Hohneker,S. Ericson,E. Perez
DOI: https://doi.org/10.1002/cncr.26313
IF: 6.9209
2012-03-01
Cancer
Abstract:Postmenopausal breast cancer (BC) patients receiving adjuvant aromatase inhibitor therapy are at risk of progressive bone loss and fractures. Zoledronic acid inhibits osteoclastic bone resorption, is effective in maintaining bone health, and may therefore be beneficial in this setting.
What problem does this paper attempt to address?